Correction to: Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway

Lu Gao¹ · Rui Yao¹ · Yuzhou Liu¹ · Zheng Wang¹ · Zhen Huang¹ · Binbin Du¹ · Dianhong Zhang¹ · Leiming Wu¹ · Lili Xiao¹ · Yanzhou Zhang¹

Published online: 6 November 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to:

Molecular and Cellular Biochemistry (2017) 429:167–177
<https://doi.org/10.1007/s11010-017-2944-x>

In the original publication of the article, Fig. 1 was published incorrectly. The correct version of Fig. 1 is provided in this correction.

The original article can be found online at <https://doi.org/10.1007/s11010-017-2944-x>.

✉ Yanzhou Zhang
yzzhang6@163.com

¹ Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou 450052, China

Fig. 1 Isorhamnetin inhibited cardiac hypertrophy in vitro. **a** Representative images of the cardiomyocytes showed the inhibitory effect of isorhamnetin on the enlargement of cardiomyocytes in response to Ang II for 48 h. **b** Quantification of cell cross-sectional area by measuring 100 random cells. **c** Real-time PCR analysis of the hypertrophy

markers atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC) incubated with different doses of isorhamnetin (5–100 μM) for 48 h subsequently treated with 1 μM Ang II for 24 h. * $P < 0.05$ versus control. # $P < 0.05$ versus Ang II-treated cells